Session 5 : Rapid Review : Part 1

Rapid Review : Part 1 by Shona Nag

Speaker :

Shona Nag

1. Expert Critique : Node-Positive Breast Ca: Door Opens to SLN After Neoadjuvant Chemo - False-negative rates lower with advances in surgical techniques (ACOSOG, Alliance Z1071 trial, The SN FNAC Study, SENTINA trial )

Author: Mateusz Opyrchal

Reference: Medpage Today ASCO Reading room

2. Axillary Lymph Node Dissection Can Largely Be Avoided in Breast Cancer (Z11 and Sound trial)

Author: Melissa Louise Pilewskie

Conference: 18th Annual Lynn Sage Breast Cancer Symposium Discussion

3. A model to predict axillary nodal pathologic complete response following neoadjuvant chemotherapy for breast cancer

Author: O Kantor

Conference: 2016 ASCO Annual Meeting, Abstract1047

4. Neratinib + fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial

Author: D Hyman

Conference: 2016 SABCS PD2-08

5. Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study

Author: Kala Visvanathan

Reference: J Clin Oncol. 2016 Nov 21

6. Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial

Author: J Balmana

Conference: 2016 ESMO 223O

7. Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials

Author: Clavarezza M

Reference: Clin Cancer Res; 22(18); 4594-603

8. Effects of perioperative lapatinib and trastuzumab, alone and in combination, in early HER2+ breast cancer - the UK EPHOS-B trial (CRUK/08/002)

Author: N. Bundred

Conference: 2016 EBCC 6LBA

9. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

Reference: Lancet Oncol. 2016 Dec 6. pii: S14702045 (16) 30631-3

10. Original Investigation: RNA Sequencing to Predict Response to Neoadjuvant Anti HER2 Therapy.A Secondary Analysis of the NeoALTTO Randomized Clinical Trial

Author: Debora Fumagalli

Reference: JAMA Oncol. 2016 Sep 29

11. Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial

Author: Amir Sonnenblick

Reference: J Natl Cancer Inst. 2016 Apr 20;108(8)

12. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases

Author: Nolan Priedigkeit

Reference: JAMA Oncol. 2016 Dec 7

13. Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1 associated and sporadic triple-negative breast cancer

Author: Nadine M. Tung

Reference: npj Breast Cancer 2, Article number:16002(2016)

14. A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBC

Author: Joel S. Parker

Reference: J Clin Oncol 33, 2015 (suppl; abstr 1083)

15. Lack of Androgen Receptor Protein May Contribute to Racial Disparities in Triple Negative Breast Cancer Outcomes

Author: Ritu Aneja

Conference: AACR Abstract B12

16. A phase II, open-label, multicentre, translational study for biomarkers of eribulin mesylate: evaluation of the utility of monitoring epithelial-to-mesenchymal transition (emt) markers on tumour cells in the malignant plural effusion of patients with metastatic breast cancer (expect-study)

Author: Watanabe

Conference: 2016 SABCS OT1-01-01

17. Prognosis of triple negative breast cancer patients who attain pathological complete response with neoadjuvant carboplatin/docetaxel and do not receive adjuvant anthracycline chemotherapy

Author: Priyanka Sharma

Conference: 2016 ASCO Annual Meeting, Abstract 1015

18. BRCA1/2 mutation prevalence in triple-negative breast cancer patients without family history of breast and ovarian cancer

Author: K Rhiem

Conference: 2016 ASCO Annual Meeting, Abstract 1090

19. Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer

Author: Chiun-Sheng Huang

Conference: 2016 ASCO Annual Meeting, Abstract 1003

20. Randomized, double blind trial to evaluate the safety and efficacy of metformin vs placebo plus neoadjuvant chemotherapy in locally advanced breast cancer

Author: C Arce-Salinas

Conference: 2016 ASCO Annual Meeting, Abstract 579n

21. A phase II, multicentre, randomised trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy

Author: Park et al

Conference: 2016 SABCS OT1-01-12

22. PAINTER: Evaluation of eribulin tolerability and correlation between a set of Polymorphisms and neuropathy in patients with metastatic breast cancer

Author: La Verde

Conference: 2016 SABCS OT1-01-05

23. Survival After Early-Stage Breast Cancer of Women Previously Treated for Depression: A Nationwide Danish Cohort Study

Author: Nis P. Suppli

Reference: JCO,November 14, 2016

24. A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer

Author: Husam Abdel-Qadir

Conference: JAMA Cardiology,2016 Oct 12

25. Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis

Author: Charles Guenancia

Reference: J Clin Oncol. 2016 Sep 10;34(26):3157 65n

26. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy

Author: D Zardavas

Reference: J. Clin. Oncol 2016 Oct 23

27. The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: A population study

Author: Hart A.Goldhar

Reference: JNCI J Natl cancer Inst (2016) 108(1)

28. Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node negative ERBB2-positive breast cancer

Author: C Dang

Reference: JAMA Oncol. 2016 Jan;2(1):29-36

29. Effect of Temporary Ovarian Suppression on Chemotherapy-Induced Amenorrhea, Pregnancy, and Outcome

Author: Pamela N. Munster

Reference: JAMA Oncol. 2016 Aug 1;2(8):1089-90

30. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline

Author: Rugo HS

Reference: J Oncol Pract. 2016 Jun;12(6):583-7

31. Do all patients with advance HER2 positive breast cancer need upfront - cemo when receiving trastuzumab ? Randamized phase III trial SAKK 22/29

Author: Pagani O

Reference: Ann Oncol. 2016 Dec 19. pii : mdw622. doi:10.1093/annonc/mdw622